2024-06-07 10:32:06 ET
Summary
- Halozyme Therapeutics, Inc. raised both its full year 2024 financial guidance and 5-year financial outlook on Thursday, sending the stock 12% higher.
- Halozyme Therapeutics continues to execute well, is buying back a significant amount of its own stock, and the shares are still reasonably valued.
- An updated analysis around this mid-cap biopharma name follows in the paragraphs below.
Today, we are following up on mid-cap biopharma concern Halozyme Therapeutics, Inc. ( HALO ) as the company issued an important FY2024 guidance update on Thursday. The company also provided updated 5-Year guidance that was triggered by a new European patent for ENHANZE®. The improved guidance resulted in a just over 12% rise in the shares in trading yesterday. This added to the rally in the equity since Halozyme reported quarterly results one month ago....
Read the full article on Seeking Alpha
For further details see:
Halozyme Therapeutics: The Story Brightens